 In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 270,000 additional Class A common shares. All of the Class A common shares are being offered by Kiniksa. Kiniksa intends to use the net proceeds from the offering to advance the clinical development of its product candidates, to fund other research and development activities and for working capital and general corporate purposes. 